Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
CYCCP's Cash to Debt is ranked higher than
94% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: 16.62 vs. CYCCP: No Debt )
CYCCP' s 10-Year Cash to Debt Range
Min: 1   Max: No Debt
Current: No Debt

Equity to Asset 0.79
CYCCP's Equity to Asset is ranked higher than
83% of the 771 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. CYCCP: 0.79 )
CYCCP' s 10-Year Equity to Asset Range
Min: -3.51   Max: 0.88
Current: 0.79

-3.51
0.88
Interest Coverage No Debt
CYCCP's Interest Coverage is ranked higher than
88% of the 443 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. CYCCP: No Debt )
CYCCP' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -6.54
M-Score: -1.50
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -1526.03
CYCCP's Operating margin (%) is ranked higher than
55% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -57.52 vs. CYCCP: -1526.03 )
CYCCP' s 10-Year Operating margin (%) Range
Min: -66250   Max: -1658.12
Current: -1526.03

-66250
-1658.12
Net-margin (%) -1341.47
CYCCP's Net-margin (%) is ranked higher than
55% of the 838 Companies
in the Global Biotechnology industry.

( Industry Median: -55.49 vs. CYCCP: -1341.47 )
CYCCP' s 10-Year Net-margin (%) Range
Min: -65040   Max: -936.62
Current: -1341.47

-65040
-936.62
ROE (%) -64.00
CYCCP's ROE (%) is ranked higher than
62% of the 885 Companies
in the Global Biotechnology industry.

( Industry Median: -27.70 vs. CYCCP: -64.00 )
CYCCP' s 10-Year ROE (%) Range
Min: -147.62   Max: -42.99
Current: -64

-147.62
-42.99
ROA (%) -50.01
CYCCP's ROA (%) is ranked higher than
61% of the 938 Companies
in the Global Biotechnology industry.

( Industry Median: -20.88 vs. CYCCP: -50.01 )
CYCCP' s 10-Year ROA (%) Range
Min: -106.85   Max: -34.56
Current: -50.01

-106.85
-34.56
ROC (Joel Greenblatt) (%) -8590.23
CYCCP's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 930 Companies
in the Global Biotechnology industry.

( Industry Median: -212.10 vs. CYCCP: -8590.23 )
CYCCP' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -10204.73   Max: -503.45
Current: -8590.23

-10204.73
-503.45
Revenue Growth (%) 51.80
CYCCP's Revenue Growth (%) is ranked higher than
97% of the 651 Companies
in the Global Biotechnology industry.

( Industry Median: -0.90 vs. CYCCP: 51.80 )
CYCCP' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 51.8
Current: 51.8

0
51.8
EBITDA Growth (%) -35.20
CYCCP's EBITDA Growth (%) is ranked higher than
59% of the 634 Companies
in the Global Biotechnology industry.

( Industry Median: -7.60 vs. CYCCP: -35.20 )
CYCCP' s 10-Year EBITDA Growth (%) Range
Min: -50.4   Max: 14.1
Current: -35.2

-50.4
14.1
EPS Growth (%) -27.80
CYCCP's EPS Growth (%) is ranked higher than
65% of the 653 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. CYCCP: -27.80 )
CYCCP' s 10-Year EPS Growth (%) Range
Min: -50.8   Max: 19.3
Current: -27.8

-50.8
19.3
» CYCCP's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with CYCCP

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Cyclacel Pharmaceuticals Inc

SymbolPriceYieldDescription
CYCCP7.308.206% Convertible Exchangeable Preferred Stock

Ratios

vs
industry
vs
history
P/B 2.50
CYCCP's P/B is ranked higher than
86% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 5.62 vs. CYCCP: 2.50 )
CYCCP' s 10-Year P/B Range
Min: 0.22   Max: 12.95
Current: 2.5

0.22
12.95
P/S 40.10
CYCCP's P/S is ranked higher than
68% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 19.28 vs. CYCCP: 40.10 )
CYCCP' s 10-Year P/S Range
Min: 6.13   Max: 1190
Current: 40.1

6.13
1190
EV-to-EBIT -1.89
CYCCP's EV-to-EBIT is ranked higher than
53% of the 988 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. CYCCP: -1.89 )
CYCCP' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -1.89

Current Ratio 4.79
CYCCP's Current Ratio is ranked higher than
77% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. CYCCP: 4.79 )
CYCCP' s 10-Year Current Ratio Range
Min: 0.96   Max: 12.96
Current: 4.79

0.96
12.96
Quick Ratio 4.79
CYCCP's Quick Ratio is ranked higher than
78% of the 934 Companies
in the Global Biotechnology industry.

( Industry Median: 3.82 vs. CYCCP: 4.79 )
CYCCP' s 10-Year Quick Ratio Range
Min: 0.96   Max: 12.96
Current: 4.79

0.96
12.96

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 8.20
CYCCP's Dividend Yield is ranked lower than
328% of the 177 Companies
in the Global Biotechnology industry.

( Industry Median: 1.16 vs. CYCCP: 8.20 )
CYCCP' s 10-Year Dividend Yield Range
Min: 0   Max: 0
Current: 8.2

Yield on cost (5-Year) 8.20
CYCCP's Yield on cost (5-Year) is ranked lower than
317% of the 183 Companies
in the Global Biotechnology industry.

( Industry Median: 1.32 vs. CYCCP: 8.20 )
CYCCP' s 10-Year Yield on cost (5-Year) Range
Min: 0   Max: 0
Current: 8.2

Share Buyback Rate -41.00
CYCCP's Share Buyback Rate is ranked higher than
60% of the 758 Companies
in the Global Biotechnology industry.

( Industry Median: -10.10 vs. CYCCP: -41.00 )
CYCCP' s 10-Year Share Buyback Rate Range
Min: 5.7   Max: -144.4
Current: -41

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) 658.90
CYCCP's Earnings Yield (Greenblatt) is ranked higher than
97% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 5.50 vs. CYCCP: 658.90 )
CYCCP' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 797.4
Current: 658.9

0
797.4
Forward Rate of Return (Yacktman) -106.64
CYCCP's Forward Rate of Return (Yacktman) is ranked higher than
58% of the 777 Companies
in the Global Biotechnology industry.

( Industry Median: -11.47 vs. CYCCP: -106.64 )
CYCCP' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 15.9   Max: 16.9
Current: -106.64

15.9
16.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:UXI2.Germany
Cyclacel Pharmaceuticals, Inc., was founded in 1996, and is incorporated Delaware. The Company is a development-stage biopharmaceutical company engaged in the development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious diseases. The Company develops and commercializes small-molecule drugs that target the various phases of cell cycle control for the treatment of cancer and other serious diseases, particularly those of high unmet medical need. Cyclacel's clinical development priorities are focused on sapacitabine: Acute myeloid leukemia, Myelodysplastic syndromes, and Non-small cell lung cancer.
» More Articles for CYCCP

Headlines

Articles On GuruFocus.com
Insider Cluster Buying Reported in Several Companies May 30 2013 
View on CYCC Sep 11 2010 
Cyclacel Pharmaceuticals Inc. Reports Operating Results (10-K/A) May 17 2010 
Cyclacel Pharmaceuticals Inc shares climb 166% in two days Jan 10 2010 
Hardest Hit Companies of the Day: Transition Therapeutics Inc., Sunesis Pharmaceuticals Inc., GenCor Dec 15 2009 

More From Other Websites
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the Seamless Phase 3... Oct 09 2014
Cyclacel to Present at BioCentury's Newsmakers in the Biotech Industry Conference Sep 19 2014
Cyclacel's CYC065 CDK Inhibitor Demonstrates Therapeutic Potential in Acute Leukemias With Mixed... Sep 18 2014
Cyclacel Pharmaceuticals Appoints Samuel L. Barker, Ph.D., to Board of Directors Sep 11 2014
Cyclacel Announces Abstract Selected for Presentation at Society of Hematologic Oncology Annual... Sep 10 2014
Cyclacel Pharmaceuticals to Present at 16th Rodman & Renshaw Annual Global Investment Conference Sep 02 2014
Cyclacel Pharmaceuticals Reports Second Quarter 2014 Financial Results Aug 12 2014
Cyclacel Pharmaceuticals to Release 2014 Second Quarter Financial Results Aug 06 2014
Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results Mar 25 2014
Cyclacel Pharmaceuticals to Release Fourth Quarter and Full Year 2013 Financial Results Mar 13 2014
Cyclacel Pharmaceuticals to Present at the 16th Annual BIO CEO & Investor Conference Feb 03 2014
Cyclacel Reviews 2013 Achievements and Announces Key Business Objectives for 2014 Jan 13 2014
Cyclacel Pharmaceuticals to Present at Biotech Showcase(TM) 2014 Conference Jan 06 2014
2013 ASH 682-06 MDS Poster Dec 09 2013
Cyclacel Reports New Phase 2 Data of Sapacitabine for MDS at ASH Dec 09 2013
Cyclacel Announces Data Safety Monitoring Board Recommendation to Continue the SEAMLESS Phase 3... Nov 25 2013
Cyclacel Reports Third Quarter 2013 Financial Results Nov 12 2013
Researchers to Present New Phase 2 Data on Sapacitabine as a Treatment for Patients With MDS at ASH... Nov 07 2013
Cyclacel Pharmaceuticals to Release Third Quarter 2013 Financial Results Nov 06 2013
New US Patents Issued Covering Sapacitabine Use With Hypomethylating Agents and Sapacitabine Dosing... Nov 05 2013

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK